Clinical Trial Update: Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of X-396 (an oral ALK inhibitor) in ALK-positive non-small cell lung cancer and other advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• X-396

Snippet

Sponsor: Xcovery Holdings, Inc. | Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED